retatrutide phase 2 obesity trial results in 28 percent average weight loss retatrutide parkinson's disease trial control Packs:30 Pack

retatrutide phase 2 obesity trial results in 28 percent average weight loss retatrutide parkinson's disease trial control Packs:30 Pack

retatrutide parkinson's disease trial drug reduces symptoms in treatment-resistant depression, clinical finds AC Immune posts positive data – New GLP-3 drug significantly slashes –

2019 Jun 1;65(6)

control

Packs:30 Pack

Il rallentamento dello svuotamento gastrico indotto dai GLP-1 RA può ridurre l’assorbimento di farmaci per via orale somministrati in concomitanza, in particolare: Contraccettivi orali (riduzione dell’efficacia) Levotiroxina e farmaci a finestra terapeutica stretta Antibiotici per os in terapie brevi L’uso combinato con insulina o sulfaniluree aumenta il rischio di ipoglicemia